Retrospective study of Erythropoiesis STimulating Agent dose ReducTion on hemodialysis patients by using anti-thrombogenic membrane
- Conditions
- Chronic renal disease
- Registration Number
- JPRN-UMIN000018431
- Lead Sponsor
- RESTART Study group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 400
Not provided
For 3 months before the beginning of observation and during observation period, patients who had fulfilled conditions below were excluded. 1) Patients who had been treated with other renal insufficiency therapies, continuous ambulatory peritoneal dialysis and hemodiafiltration, excluding hemodialysis. 2) Patients to whom Epoetin Beta Pegol (CERA) had been prescribed. 3) Patients to whom blood transfusion had been conducted. 4) Patients who had been hospitalized for more than 2 weeks. 5) Patients who had become pregnant or given birth. 6) Patients who had hematologic diseases excluding renal anemia. 7) Patients who had been treated for a malignant tumor. 8) Patients who is judged as the inadequate subject of this study by the doctor.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method